argenx SE (ARGX.BR)
EUR 524.2
(0.15%)
EUR 524.2
(0.15%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -417.15 Million EUR | 42.03% |
| 2022 | -719.66 Million USD | -106.36% |
| 2021 | -348.74 Million USD | 32.13% |
| 2020 | -513.83 Million EUR | -156.9% |
| 2019 | -200.01 Million EUR | -113.62% |
| 2018 | -93.62 Million EUR | -240.32% |
| 2017 | -27.51 Million EUR | -22.15% |
| 2016 | -22.52 Million EUR | -32.02% |
| 2015 | -17.06 Million EUR | -30.6% |
| 2014 | -13.06 Million EUR | -51.85% |
| 2013 | -8.6 Million EUR | 35.28% |
| 2012 | -13.29 Million EUR | -181.75% |
| 2011 | -4.71 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -45.46 Million EUR | -69.8% |
| 2024 Q1 | -93.42 Million USD | 36.9% |
| 2023 Q3 | -80.58 Million USD | 21.06% |
| 2023 Q1 | -103.74 Million USD | 8.8% |
| 2023 Q2 | -102.09 Million USD | 1.59% |
| 2023 FY | -417.15 Million EUR | 42.03% |
| 2023 Q4 | -138.62 Million USD | -72.02% |
| 2022 FY | -719.66 Million USD | -106.36% |
| 2022 Q3 | -208.63 Million USD | -19.53% |
| 2022 Q4 | -113.75 Million USD | 45.48% |
| 2022 Q1 | -222.72 Million USD | 3.55% |
| 2022 Q2 | -174.54 Million USD | 21.63% |
| 2021 Q1 | -13 Thousand EUR | 99.99% |
| 2021 FY | -348.74 Million USD | 32.13% |
| 2021 Q2 | 95.13 Million USD | 731915.38% |
| 2021 Q3 | -212.95 Million USD | -323.84% |
| 2021 Q4 | -230.91 Million USD | -8.43% |
| 2020 Q4 | -227.44 Million EUR | 0.0% |
| 2020 FY | -513.83 Million EUR | -156.9% |
| 2020 Q2 | -210.97 Million EUR | 0.0% |
| 2019 Q1 | -6.78 Million EUR | 82.47% |
| 2019 FY | -200.01 Million EUR | -113.62% |
| 2019 Q4 | -75.19 Million EUR | -53.81% |
| 2019 Q3 | -48.88 Million EUR | 11.34% |
| 2019 Q2 | -55.14 Million EUR | -712.86% |
| 2018 Q2 | -11.91 Million EUR | 31.7% |
| 2018 Q3 | -25.58 Million EUR | -114.78% |
| 2018 FY | -93.62 Million EUR | -240.32% |
| 2018 Q1 | -17.44 Million EUR | -49.3% |
| 2018 Q4 | -38.69 Million EUR | -51.23% |
| 2017 Q1 | -8.97 Million EUR | -6.57% |
| 2017 Q2 | 1.24 Million EUR | 113.9% |
| 2017 Q4 | -11.68 Million EUR | -44.13% |
| 2017 Q3 | -8.1 Million EUR | -749.93% |
| 2017 FY | -27.51 Million EUR | -22.15% |
| 2016 Q3 | -5.92 Million EUR | -23.23% |
| 2016 Q1 | -3.37 Million EUR | 39.09% |
| 2016 FY | -22.52 Million EUR | -32.02% |
| 2016 Q2 | -4.8 Million EUR | -42.66% |
| 2016 Q4 | -8.41 Million EUR | -42.08% |
| 2015 Q2 | -4.63 Million EUR | -32.48% |
| 2015 FY | -17.06 Million EUR | -30.6% |
| 2015 Q4 | -5.53 Million EUR | -62.93% |
| 2015 Q3 | -3.39 Million EUR | 26.71% |
| 2015 Q1 | -3.49 Million EUR | 25.08% |
| 2014 Q2 | -3.73 Million EUR | -43.16% |
| 2014 Q3 | -2.05 Million EUR | 45.08% |
| 2014 Q4 | -4.66 Million EUR | -127.61% |
| 2014 FY | -13.06 Million EUR | -51.85% |
| 2014 Q1 | -2.6 Million EUR | -23.68% |
| 2013 Q2 | -4 Million EUR | -67.07% |
| 2013 Q3 | -97.6 Thousand EUR | 97.56% |
| 2013 Q4 | -2.1 Million EUR | -2061.35% |
| 2013 Q1 | -2.39 Million EUR | 0.0% |
| 2013 FY | -8.6 Million EUR | 35.28% |
| 2012 FY | -13.29 Million EUR | -181.75% |
| 2011 FY | -4.71 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nicox S.A. | -17.5 Million EUR | -2283.325% |
| European Medical Solutions | -135 Thousand EUR | -308902.489% |
| FERMENTALG | -11.8 Million EUR | -3432.803% |
| BioSenic S.A. | -7.04 Million EUR | -5825.474% |
| Celyad Oncology SA | -8.45 Million EUR | -4832.64% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -2508.35% |
| Onward Medical N.V. | -35.46 Million EUR | -1076.306% |
| Oxurion NV | -12.11 Million EUR | -3344.702% |
| PHAXIAM Therapeutics S.A. | -23.66 Million EUR | -1663.116% |
| Financière de Tubize SA | -2.14 Million EUR | -19357.016% |
| UCB SA | 604 Million EUR | 169.065% |